Incyte Corp

4 de nov. de 2026, 21:02 UTC

Incyte Corp will present over 30 abstracts at the ASH Annual Meeting, including Phase 1 data for INCA033989 and updates on myelofibrosis treatments.

3 de nov. de 2026, 21:41 UTC

Incyte Corp shares are declining in after-market trading, marking the fourth consecutive session of lower closes and reaching a low below Tuesday's close.

2 de nov. de 2026, 20:26 UTC

Bernstein SocGen's Jeffrey Walch raises Incyte Corp's price target to $108.00 from $104.00 while maintaining a Market Perform rating.

30 de out. de 2026, 23:16 UTC

Incyte Corp shares are modestly higher in after-market hours, remaining 5.89% above their 20-day moving average and near the upper end of their one-month range.

29 de out. de 2026, 23:01 UTC

Incyte Corp is trading higher in after-market hours, reaching a high point and well above its 20-day moving average since Thursday's close.

28 de out. de 2026, 20:07 UTC

Incyte Corp shares are advancing as investors monitor the Federal Reserve's decision to maintain interest rates amid rising inflation, despite an earlier pullback.

27 de out. de 2026, 21:01 UTC

Incyte Corp shares declined in after-market trading after initially rising, reflecting significant volatility within the broader context of its one-month trading range.

26 de out. de 2026, 21:01 UTC

Incyte Corp shares advanced modestly in after-market trading, maintaining a cumulative return of 0.83% since Monday's close.

23 de out. de 2026, 20:07 UTC

Incyte Corp shares are declining amid a broader market downturn influenced by rising oil prices, inflation concerns, and geopolitical tensions.

22 de out. de 2026, 20:07 UTC

Incyte Corp shares are advancing, continuing a notable upward trajectory since Wednesday's close, reaching their peak just before the close on Thursday.

21 de out. de 2026, 20:07 UTC

Incyte Corp shares are declining, reflecting broader market weakness, and are approaching the low end of their one-month range amid a significant drop since Tuesday's close.

20 de out. de 2026, 20:08 UTC

Morgan Stanley initiates coverage on Incyte Corp with an Equalweight rating and a price target of $119.00, following the stock's prior close of $113.25.

19 de out. de 2026, 19:36 UTC

Incyte Corp will present new data on investigational therapies INCB161734 and INCA33890 at the ESMO Congress 2026, scheduled for October 23 to 27 in Madrid.

17 de out. de 2026, 00:01 UTC

Incyte Corp shares are trading lower in after-market hours, reversing an initial gain and reaching their lowest point of the day.

16 de out. de 2026, 20:13 UTC

Incyte Corp shares are modestly higher in after-market trading, maintaining a slight gain.

15 de out. de 2026, 21:03 UTC

Incyte Corp shares are advancing in after-market trading, continuing a strong performance after three consecutive sessions of gains, though still below the 20-day moving average.

14 de out. de 2026, 20:07 UTC

Truist Securities maintains Hold rating on Incyte Corp and raises price target to $115 in a report published today.

13 de out. de 2026, 20:02 UTC

Incyte Corp shares fell sharply, reaching a low point shortly after the market opened and remaining below its 20-day moving average.

12 de out. de 2026, 21:01 UTC

Incyte Corp shares declined in after-market trading, continuing a downward trend and remaining notably below its 20-day moving average.

9 de out. de 2026, 20:07 UTC

Incyte Corp shares traded roughly flat, peaking at a cumulative return of 0.90%, but remain significantly below their 20-day moving average.

8 de out. de 2026, 20:07 UTC

RBC Capital raised Incyte's price target to $114 and maintained its Sector Perform rating ahead of the company's Q3 results on October 29, 2026.

7 de out. de 2026, 21:31 UTC

Incyte Corp is trading lower in after-market hours, closing at its lowest point of the day and below its 20-day moving average.

6 de out. de 2026, 19:50 UTC

Incyte Corp shares fell sharply, extending a six-session decline amid notable volatility, with current prices significantly below the 20-day moving average.

5 de out. de 2026, 21:01 UTC

Incyte Corp is down significantly in after-market trading, marking its seventh consecutive session lower and remaining well below its 20-day moving average.

2 de out. de 2026, 23:05 UTC

Incyte Corp saw a modest increase in after-market trading, reaching its highest level since Friday's close, despite notable volatility during the session.

1 de out. de 2026, 23:15 UTC

Incyte Corp declined in after-market hours, marking its fourth consecutive session of losses and remaining significantly below its 20-day moving average.

30 de set. de 2026, 20:01 UTC

Incyte Corp shares fell sharply, remaining below their 20-day moving average and positioned near the lower end of their one-month range.

29 de set. de 2026, 20:07 UTC

Incyte Corp's shares fell sharply, reaching a midday low and finishing weaker, remaining below their 20-day moving average and near the lower end of their one-month trading range.

28 de set. de 2026, 21:01 UTC

Incyte Corp has advanced in after-market trading, reaching its highest level for the session amid broader biotechnology sector activity and remaining above its 20-day moving average.

25 de set. de 2026, 19:36 UTC

Incyte shares fell after FDA approved Atebrioz for fibrodysplasia ossificans progressiva, as traders await clarity on the drug's commercial prospects.